Belvarafenib

SKU: orb1301634

Description

Belvarafenib (HM95573) is a pan-RAF inhibitor exhibiting potent activity against B-RAF, B-RAF V600E, and C-RAF. It demonstrates antitumor efficacy in preclinical models, supporting its investigation in oncology research for RAF-driven cancers, both in vitro and in vivo.

Research Area

Signal Transduction

Key Properties

• CAS Number: 1446113-23-0
• MW: 478.93
• Purity: 99.65% (May vary between batches)
• Formula: C₂₃H₁₆ClFN₆OS
• SMILES: Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
• Target: Raf
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:1 mg/mL (2.09 mM);DMSO:25 mg/mL (52.2 mM)

Bioactivity

• Target IC50:
  C-Raf:5 nM|B-Raf:56 nM|B-Raf (V600E):7 nM
• In Vivo:
  METHODS: Data were collected from 192 patients with melanoma who underwent NGS between November 2017 and May 2023.EAP patients were treated with 450 mg of Belvarafenib (HM95573) twice daily. RESULTS Six patients with NRAS or RAF alterations were treated with Belvarafenib (HM95573), and 50% of the patients had control of their disease, including two patients with significant outcomes.
  Read more...
• In Vitro:
  Belvarafenib (HM95573) inhibited B-RAF, B-RAFv600E and C-RAF with IC50 values of 56, 7 and 5 nM, respectively.

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Belvarafenib, GDC 5573, GDC5573, GDC-5573, Inhibitor, HM95573, HM-95573, HM 95573, inhibit, RG 6185, RG6185, RG-6185, Raf, Raf kinases

Compound Identifiers

PubChem CID

89655386